Telix Pharmaceuticals (NASDAQ:TLX) Sets New 52-Week High – Time to Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $12.48 and last traded at $12.3940, with a volume of 393964 shares. The stock had previously closed at $11.98.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, September 2nd. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Performance

The business’s 50-day simple moving average is $11.23 and its two-hundred day simple moving average is $10.06. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently modified their holdings of the business. XY Capital Ltd lifted its stake in shares of Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after acquiring an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at $1,731,000. Bank of America Corp DE increased its position in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC raised its stake in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.